Free Trial
OTCMKTS:BETRF

BetterLife Pharma (BETRF) Stock Price, News & Analysis

BetterLife Pharma logo
$0.06 -0.01 (-11.23%)
As of 04/1/2025 09:56 AM Eastern

About BetterLife Pharma Stock (OTCMKTS:BETRF)

Key Stats

Today's Range
$0.06
$0.07
50-Day Range
$0.06
$0.11
52-Week Range
$0.05
$0.15
Volume
1,277 shs
Average Volume
16,914 shs
Market Capitalization
$7.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Remove Ads

BetterLife Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

BETRF MarketRank™: 

BetterLife Pharma scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for BetterLife Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BetterLife Pharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BetterLife Pharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BetterLife Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.02% of the float of BetterLife Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    BetterLife Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BetterLife Pharma has recently decreased by 41.53%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BetterLife Pharma does not currently pay a dividend.

  • Dividend Growth

    BetterLife Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of BetterLife Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    BetterLife Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BetterLife Pharma has recently decreased by 41.53%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BetterLife Pharma has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for BetterLife Pharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.01% of the stock of BetterLife Pharma is held by institutions.

  • Read more about BetterLife Pharma's insider trading history.
Receive BETRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BetterLife Pharma and its competitors with MarketBeat's FREE daily newsletter.

BETRF Stock News Headlines

BetterLife Pharma Appoints New Director
BetterLife Pharma Appoints New Director
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
BetterLife Pharma Inc. (OTCMKTS:BETRF) Short Interest Update
BetterLife Announces Debt Conversions
See More Headlines

BETRF Stock Analysis - Frequently Asked Questions

BetterLife Pharma's stock was trading at $0.0720 on January 1st, 2025. Since then, BETRF stock has decreased by 18.8% and is now trading at $0.0585.
View the best growth stocks for 2025 here
.

Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/02/2025
Next Earnings (Estimated)
5/27/2025
Fiscal Year End
1/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BETRF
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-1.17

Miscellaneous

Free Float
84,449,000
Market Cap
$7.57 million
Optionable
Not Optionable
Beta
1.41
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:BETRF) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners